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Abstract
Background: An abundant class of intronic microRNAs (miRNAs) undergoes atypical Drosha-independent biogenesis
in which the spliceosome governs the excision of hairpin miRNA precursors, called mirtrons. Although nearly
500 splicing-dependent miRNA candidates have been recently predicted via bioinformatic analysis of human
RNA-Seq datasets, only a few of them have been experimentally validated. The detailed mechanism of miRNA
processing by the splicing machinery and the roles of mirtronic miRNAs in cancer are yet to be uncovered.
Methods: We experimentally examined whether biogenesis of certain miRNAs is under a splicing control by analyzing
their expression levels in response to alterations in the 5′- and 3′-splice sites of a series of intron-containing minigenes
carrying appropriate miRNAs. The expression levels of the miRNAs processed from mirtrons were determined
by quantitative real-time PCR in five digestive tract (pancreas PANC-1, SU.86.86, T3M4, stomach KATOIII, colon
HCT116) and two excretory system (kidney CaKi-1, 786-O) carcinoma cell lines as well as in pancreatic, stomach, and
colorectal tumors. Transiently expressed SRSF1 and SRSF2 splicing factors were quantified by western blotting in the
nuclear fractions of HCT116 cells.
Results: We found that biogenesis of the human hsa-miR-1227-3p, hsa-miR-1229-3p, and hsa-miR-1236-3p is
splicing-dependent; therefore, these miRNAs can be assigned to the class of miRNAs processed by a non-canonical
mirtron pathway. The expression analysis revealed a differential regulation of human mirtronic miRNAs in various
cancer cell lines and tumors. In particular, hsa-miR-1229-3p is selectively upregulated in the pancreatic and stomach
cancer cell lines derived from metastatic sites. Compared with the healthy controls, the expression of hsa-miR-1226-3p
was significantly higher in stomach tumors but extensively downregulated in colorectal tumors. Furthermore,
we provided evidence that overexpression of SRSF1 or SRSF2 can upregulate the processing of individual
mirtronic miRNAs in HCT116 cells.
Conclusions: An interplay of different splicing factors, such as SRSF1 or SRSF2, may alter the levels of miRNAs
of mirtron origin in a cell. Our findings underline the specific expression profiles of mirtronic miRNAs in colorectal,
stomach, and pancreatic cancer.
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Background
All multi-exon human genes undergo constitutive and
alternative splicing, a very precise process which is cru-
cial for regulation of gene expression and generation of
proteomic and functional diversity [1]. In the cell, RNA
splicing takes place in the nucleus within a large macro-
molecular complex, the spliceosome, which consists of
five small nuclear ribonucleoproteins (snRNPs) and over
a few hundred auxiliary proteins [2]. Somatic mutations
or dramatic alterations in the amount of splicing factors
under pathologic conditions, particularly in human cancers,
have been observed, thus resulting in abnormal expression
of tumor suppressors or oncogenes [3–5]. Furthermore,
various types of cancer have been linked to dysregulation of
microRNAs (miRNAs), short non-coding RNAs that post-
transcriptionally regulate gene expression in mammals [6].
Although the majority of miRNA genes possess their own
internal promoters that are regulated by different transcrip-
tion and epigenetic factors, approximately one third of
them are processed from introns of protein-coding or long
non-coding RNAs genes [7]. That provides means for
coupled regulation of miRNA maturation and mRNA spli-
cing. However, the spatiotemporal control of miRNA
expression by splicing factors has not been elucidated.
Canonical pri-miRNA is cleaved by Drosha/DGCR8
complex to form pre-miRNA hairpin, which is recognized
by Exportin-5 and transferred to the cytoplasm. After pro-
cessing by Dicer ribonuclease, the guide miRNA strand of
mature miRNA/miRNA* duplex is incorporated into a
RNA-induced silencing complex (RISC). An alternative
pathway of miRNA biogenesis was lately described in eu-
karyotes [8, 9]. Short introns containing miRNAs, termed
mirtrons, are spliced and debranched into pre-miRNA
hairpin mimics that appear to bypass Drosha cleavage
(Additional file 1: Figure S1). Debranched mirtrons enter
the canonical miRNA pathway during nuclear export.
Mirtrons were originally described in flies and worms
[10, 11], but similar loci (i.e., short hairpin introns associ-
ated with small RNA reads extending to intronic termini)
were later predicted in a range of plants and mammalians,
including humans [12–14]. Based on the nature of
terminal overhangs, four distinct mirtron subtypes are
recognized: conventional (hairpin without tails), 3′-tailed,
5′-tailed, and two-tailed [14].
Despite the fact that the first splicing-dependent human
mirtrons were annotated in 2007 [15] and a large number
of splicing-derived miRNAs have been predicted by bio-
informatic analysis of deep sequencing data [12, 14], only
two of them, hsa-miR-877-5p and hsa-miR-1226-3p, were
experimentally proven to be directly affected by splicing
[16, 17]. 478 mirtron candidates predicted by Wen et al.
[14] could cover a significant part of the total human
miRNA population (2588 mature miRNA entries accord-
ing to miRBase release 21 [18]), but little is still known
about their impact on the expression of disease-related
genes. It is currently shown that the mirtronic miRNA
hsa-miR-1226-3p may function as an oncosuppressor by
downregulating the mucin 1 oncoprotein and the hsa-
miR-1226-3p level is decreased in breast cancer cells [19].
hsa-miR-1236-3p processed from a putative mirtron
downregulates alpha fetoprotein, thus leading to the inhib-
ition of the PI3K/Akt pathway in hepatoma cancer cell
lines [20], and negatively regulates the vascular endothelial
growth factor receptor VEGFR-3 during inflammatory
lymphangiogenesis [21]. In addition, a miR-1236-3p anti-
sense oligonucleotide inhibits the glioma tumor cell
growth and proliferation [22]. Overexpression of hsa-miR-
877-5p was observed in metastatic melanoma [23] and
endometrial serous adenocarcinomas [24], but no bio-
logical function was determined. Yet, very little is known
about the expression profiles of mirtron-derived miRNAs
in tumors or cancer cells. There is a high possibility that
the expression levels of splicing factors can not only affect
alternative pre-mRNA splicing but cause changes in mir-
tronic miRNA expression as well.
In this study, we examined eight putative mirtrons and
provided experimental evidence that human hsa-miR-
1227-3p, hsa-miR-1229-3p, and hsa-miR-1236-3p could
be assigned to the class of mirtronic miRNAs. Digestive
and excretory system cancer cell lines, as well as digest-
ive system tumors tissues, display varying expression
profiles of the previously identified hsa-miR-1226-3p
and the two newly validated mirtronic miRNAs. Finally,
we found that overexpression of well-known splicing
factors SRSF1 and SRSF2 increased the abundance of
some mirtron-derived miRNAs in colorectal HCT116
cancer cells.
Results
Experimental validation of new splicing-dependent human
mirtronic miRNAs
The vast majority of nearly 500 mirtron-derived miRNA
candidates, except hsa-miR-887 and hsa-miR-1226-3p
processed from conventional mirtrons, are still listed as
experimentally unverified [14, 16, 17]. In order to ex-
pand the number of comprehensively validated miRNAs
of mirtron origin, we examined eight putative human
mirtrons ascribed to three different subtypes (Additional
file 1: Figure S2). Putative human conventional mirtron-
derived hsa-miR-1227-3p, hsa-miR-1229-3p, hsa-miR-
1236-3p, and hsa-miR-1238-3p [15] and 3′-tailed
mirtron-derived hsa-miR-3940-5p and hsa-miR-6850-5p
were identified in short 69–102 nucleotide introns,
whereas hsa-miR-3064-5p and hsa-miR-6515-5p were
processed from both long (1236 nt) and short (88 nt) 5′-
tailed mirtrons [12]. To establish dependence of their
biogenesis on mRNA splicing, we constructed plasmids
harboring minigenes of two or one intron spanned by
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three and two coding exons, respectively (Fig. 1a). Wild-
type (WT) minigenes encompassed the natural introns
while MUT variants of minigenes contained the intron,
which hosted miRNA, with mutations affecting the G resi-
dues at 5′ splice donor (GU changed to CU) and 3′ splice
acceptor (AG changed to AC) sites. A plasmid with the
MG1226/DHX30 minigene containing the functionally
proven mirtronic hsa-miR-1226-3p [16] was used as a
positive control. As shown in Fig. 1b, the introns are ef-
fectively excised in the majority of the analyzed mRNAs
processed from plasmids with WT minigenes in colorectal
carcinoma HCT116 cells. In contrast, mRNAs from the
MUT variants retained the unspliced exon–intron–exon
structure. No reverse transcription (RT)-PCR products
MG1226/DHX30 
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Fig. 1 (See legend on next page.)
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were detected in the control samples obtained from cells
transfected with an insert-less vector (data not shown)
under similar reaction conditions, confirming that the ma-
jority of target mRNAs in cells were synthesized from the
analyzed minigenes.
Simultaneous quantitation of individual miRNAs by
real-time qPCR analysis revealed a 10–2000-fold enrich-
ment of all tested intronic miRNAs when a plasmid with
the WT minigene structure was transfected into the
HCT116 cell line (Table 1 and Fig. 1c, brown bars).
These results provide convincing evidence that the
tested intronic regions generate specific miRNAs. A differ-
ent outcome was observed for miRNA formation in cells
transfected with the splicing-deficient MUT minigenes
(Fig. 1c, orange bars). The expression levels of hsa-miR-
1226-3p, hsa-miR-1227-3p, hsa-miR-1229-3p, and hsa-
miR-1236-3p dramatically decreased and comprised less
than 5 % of the levels observed for the WT minigenes
(Table 1). These results convincingly confirmed that the
biogenesis of hsa-miR-1226-3p, hsa-miR-1227-3p, hsa-
miR-1229-3p, and hsa-miR-1236-3p is strictly splicing-
dependent, thus the efficiency of the splicing machinery
defines the quantity of these miRNAs. The hsa-miR-1238-
3p expression level in the cell lines containing the intron
excision-deficient MUT variant of minigene was more
than 400-fold higher as compared to that in cells lacking
the minigene. Different results were obtained with 5′- and
3′-tailed mirtrons, where disruption of the splicing sites
did not inhibit the accumulation of hsa-miR-3064-5p, hsa-
miR-6515-5p, hsa-miR-3940-5p, and hsa-miR-6850-5p
(Fig. 1). Due to the observed splicing-independent matur-
ation, these miRNAs cannot be considered bona fide mir-
tronic miRNAs.
Differential expression of miRNAs processed from
conventional mirtrons in cancer cell lines
While a role of canonical Drosha/DGCR8-dependent
miRNAs in human diseases is well recognized, there is
much to be learned about the implications of mirtronic
miRNAs in cancer development and their possible diag-
nostic potential. Carcinoma cell lines derived from vari-
ous digestive system organs (pancreas PANC-1,
SU.86.86, T3M4, stomach KATOIII, colon HCT116) or
the excretory system (kidney CaKi-1, 786-O) were
chosen to define whether the expression of the human
mirtronic miRNAs hsa-miR-1226-3p, hsa-miR-1227-3p,
hsa-miR-1229-3p, and hsa-miR-1236-3p and canonical
hsa-miR-1238-3p varies between the cancerous cells.
The human embryonic kidney HEK 293A cells were
used as a reference cell line to which the other cell lines
were compared. The results are summarized in Fig. 2,
Table 2, and Additional file 1: Figure S3.
The expression pattern of the tested mirtron-derived
miRNAs revealed a unique miRNA signature of individ-
ual cancer cell lines (Fig. 2). The abundance of two of
them, hsa-miR-1226-3p and hsa-miR-1227-3p, was re-
duced two- to five-fold in all cancer cell lines relative to
the embryonic kidney HEK 293A cells. The highest
downregulation was observed in the kidney carcinoma
CaKi-1 and 786-O cells. In contrast, hsa-miR-1229-3p
and hsa-miR-1236-3p showed significant variations
(See figure on previous page.)
Fig. 1 Identification of splicing-dependent miRNAs processed from mirtrons. a Schematic representation of exon–intron structures of analyzed human
minigenes. Boxes and lines indicate exons and introns, respectively. Introns containing validated mirtronic miRNA hsa-mir-1226-3p or predicted miRNAs
hsa-mir-1227-3p, hsa-mir-1229-3p, hsa-mir-1236-3p, and hsa-mir-1238-3p processed from conventional; hsa-miR-3064-5p and hsa-miR-6515-5p
from 5′-tailed; and hsa-miR-3940-5p and hsa-miR-6850-5p from 3′-tailed mirtrons are depicted as red lines. WT, wild-type sequences, and
MUT, minigenes carrying the double mutant with GT to CT and AG to AC changes (affected nucleotides are marked in red), in 5′-donor
and 3′-acceptor splice sites, respectively. b Splicing analysis of minigene transcripts in transfected HCT116 cells. The position of oligonucleotides
used for RT-PCR analysis of mRNA transcripts produced by minigene constructs is indicated by white arrows in section a. Control reactions, RT, were
performed without prior reverse transcription to exclude DNA contamination. Unspliced form indicates transcript retaining mirtronic intron; spliced,
intron is excised. TBP — loading control. c miRNA expression in colorectal cancer HCT116 cell line transfected with native (WT) or splicing-
deficient (MUT) minigenes was analyzed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Expression level of RNU48
was used as endogenous reference for data normalization. The experiments were performed in at least three biological replicates. The error bars
represent calculated values for standard deviation
Table 1 Alterations of miRNA expression level in cells transfected






Hosted on conventional mirtron
hsa-miR-1226-3p 81 ± 36 1.5 ± 0.3 1.9
hsa-miR-1227-3p 405 ± 204 24 ± 8 5.9
hsa-miR-1229-3p 1633 ± 106 4.1 ± 2.1 0.3
hsa-miR-1236-3p 747 ± 217 2.6 ± 0.5 0.3
hsa-miR-1238-3p 1772 ± 1289 425 ± 322 24
Hosted on 5′-tailed mirtron
hsa-miR-3064-5p 27 ± 13 47 ± 29 173
hsa-miR-6515-5p 875 ± 162 1541 ± 576 176
Hosted on 3′-tailed mirtron
hsa-miR-3940-5p 9.1 ± 1.7 13 ± 0.3 141
hsa-miR-6850-3p 20 ± 12 57 ± 38 286
aFold change
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among cancer cell lines and have a potential to be
exploited for profiling specific cancer cell types. Correla-
tions were found between the hsa-miR-1229-3p expres-
sion pattern and tissue origin — a steep increase in the
mirtronic miRNA abundance was detected in three lines
(SU.86.86, T3M4, and KATOIII) derived from metastatic
sites as opposed to those derived from primary tumors.
In particular, the PANC-1 cells (established from pancre-
atic carcinoma of ductal origin) showed a 14-fold reduction
of this mirtronic miRNA as compared to the SU.86.86 cells
(derived from pancreatic ductal carcinoma metastatic site
in the liver). Moreover, hierarchical clustering based on
relative expression variations for mirtronic miRNAs identi-
fied the majority of the cell lines derived from metastatic
sites as a unique group (Fig. 2). However, further studies
are required to ascertain whether hsa-miR-1229-3p is
selectively upregulated in metastatic tumor tissues.
The levels of canonical hsa-miR-1238-3p expression in
the majority of cancer cells, with the exception of SU.86.86
and HCT116, were similar to embryonic HEK 293A cells.
Expression profiling of mirtronic miRNAs in pancreatic,
colorectal, and stomach tumors
To further explore the impact of mirtronic miRNAs
on human cancer development, we analyzed whether
mirtron-derived miRNAs are differentially expressed
in digestive system tumors (pancreatic, colorectal, and
stomach) as compared to normal solid tissue samples
of the same organ.
The tissue analysis results revealed that tumors of dif-
ferent organs have a characteristic signature of mirtronic
miRNA expression (Fig. 3 and Table 3). We found that
only one out of five tested miRNAs, hsa-miR-1226-3p,
was significantly under-expressed in the colorectal tumor
(p < 0.001). Conversely, the expression level of this miRNA
was profoundly elevated in stomach cancer compared to
that in non-tumor tissues (p < 0.001). Whereas steady
levels of hsa-miR-1226-3p were detected in pancreatic
cancer and healthy pancreatic tissues, two other mirtronic
miRNAs, hsa-miR-1227-3p (p = 0.028) and hsa-miR-1236-
3p (p = 0.017), were significantly downregulated in this
tumor type. Thus, different expression profiles of mirtro-
nic miRNAs were observed not only in cancerous cell
lines but also in digestive organ tumors.
Effect of splicing factors SRSF1 and SRSF2 on biogenesis
of mirtronic miRNAs
Despite a considerable progress in the study of biogenesis







































































Fig. 2 Heatmap of mirtronic miRNA expression in human cancer cell
lines. Cell lines are in rows, miRNAs in columns. The relative expression
of each miRNA was determined by real-time PCR; data are presented
as log2 fold changes relative to embryonic cell line HEK293A. The
heatmap colors represent relative miRNA expression as indicated in
the color key: red, higher expression; green, lower expression; and
black, no difference. Dendrogram of hierarchy clustering analysis is
presented at the left
Table 2 Differential expression of mirtronic miRNAs in pancreas, kidney, colon, and stomach cancer cell lines
Organ Cell line miRNAs of mirtron origin Non-mirtronic miRNA
miR-1226-3p miR-1227-3p miR-1229-3p miR-1236-3p miR-1238-3p
Pancreas PANC-1 −2.8 ± 1.8a −1.7 ± 0.3a −2.8 ± 0.9a −1.4 ± 0.2 −1.2 ± 0.6
SU.86.86 −3.4 ± 0.9a −2.1 ± 0.4a +5.0 ± 2.7b +3.8 ± 0.6b +2.8 ± 0.9b
T3M4 −2.2 ± 0.4a −2.6 ± 0.4a +2.1 ± 0.3b +1.9 ± 0.4b +1.3 ± 0.2
Kidney CaKi-1 −4.9 ± 2.1a −3.9 ± 1.6a −1.2 ± 0.6 +1.3 ± 0.7 1.0 ± 0.8
786-O −4.6 ± 2.2a −2.6 ± 0.7a −1.1 ± 0.2 −1.8 ± 0.2a −1.1 ± 0.2
Colon HCT116 −2.7 ± 0.8a −2.2 ± 0.8a −1.3 ± 0.2 1.0 ± 0.7 −4.2 ± 0.3a
Stomach KATOIII −1.9 ± 0.3a −2.0 ± 0.4a +2.7 ± 0.3b −2.2 ± 0.3a +1.3 ± 0.0
Fold changes higher than 1.5 were statistically significant (p < 0.05)
aReduced expression compared to the non-cancerous HEK 293A cells
bEnhanced expression
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mirtronic intron splicing are not known. Commonly, the
efficiency of the macromolecular spliceosome complex is
controlled by associated protein cofactors called splicing
factors (SFs). However, it is not known whether the spli-
cing proteins directly affect the biogenesis of mirtronic
miRNAs in human cells. To evaluate the regulatory func-
tion of specific SF in maturation of mirtron-derived miR-
NAs, we overexpressed two essential sequence-specific
SFs of serine-arginine-rich (SR) protein family, SRSF1
(also known as SF2/ASF) and the SRSF2 (also known as
SC35), in human HCT116 cells and measured cellular
levels of three splicing-dependent miRNAs, hsa-miR-
1226-3p, hsa-miR-1227-3p, and hsa-miR-1229-3p. These
prototypical SR proteins play an important role in the
regulation of both constitutive and alternative pre-mRNA
splicing [25]. In addition, SRSF1 is also involved in pri-
miRNA processing [26].
Western-blot analysis revealed a 3.2- and 1.6-fold in-
crease in SRSF1 and SRSF2 protein yield in the nuclear
extracts, respectively, after transfection of human HCT116
cells with the pSRSF1 or pSRSF2 constructs (Fig. 4a). Since
the RNA splicing occurs within the nucleus, it is plausible
that only biologically active intranuclear fractions of cellu-
lar SF were quantified in our experiments. Concomitant
evaluation of the miRNA expression levels by RT-qPCR
showed a statistically significant increase of hsa-miR-1229-
3p but not hsa-miR-1226-3p or hsa-miR-1227-3p in re-
sponse to SRSF1 overexpression (Fig. 4b, the diagram at
the left, and Table 4). Whereas a significant upregulation of
SRSF2-dependent expression was observed for hsa-miR-
1227-3p (p = 0.008) and miR-1229-3p (p = 0.008), the hsa-
miR-1226-3p did not exhibit statistically different (p = 0.15)
expression levels between the HCT116 line and the line
overexpressing the SRSF2 SF (Fig. 4b, the diagram at the
right). A bioinformatic analysis of the splicing signals using
the Human Splicing Finder online tool [27] identified
putative consensus motifs typical for SRSF1 and SRSF2
in exons proximal to hsa-miR1227- and hsa-miR1229-
containing introns, respectively (Additional file 1:
Figure S3). These findings are in agreement with the
observation that the overexpression of SRSF1 had the
largest impact on the expression of hsa-miR-1229-3p,
whereas SRSF2 on hsa-miR-1227-3p. SRSF1-specific
and SRSF2-specific enhancers established nearby hsa-















































Fig. 3 Variability in expression of mirtronic miRNAs in colorectal (a),
stomach (b), and pancreatic adenocarcinoma (c) tissues. ΔCt values
are quantified relative to RNU48 (ΔCt = ΔCmiR − ΔCRNU48). The line
within a box marks the median value, the boundaries of the box
indicate the 25th and 75th percentiles, the asterisks indicate the 90th
and 10th percentiles, and the circles represent outliers. p values on
top of the bars mark statistically significant differences between
pairs. White vertical boxplots represent data from healthy tissues; gray
from tumors
Table 3 Expression of mirtronic miRNAs in colorectal, stomach, and pancreatic cancerous tissues compared to healthy tissues
Cancerous tissue miRNAs of mirtron origin Non-mirtronic miRNA
miR-1226-3p miR-1227-3p miR-1229-3p miR-1236-3p miR-1238-3p
Colorectal − No change No change No change No change
Stomach + No change No change No change No change
Pancreatic No change − No change − No change
Data were considered significant for p < 0.05
− reduced expression compared to the non-cancerous tissue, + increased expression
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regulatory element with overlapping enhancer and silen-
cer functions causing uneven expression levels of this
miRNA in different biological repeats and high p values.
Overall, our results lead to a conclusion that altered
expression of a particular SF may affect the levels of
mirtronic miRNAs in the cell.
Discussion
To date, nearly 500 human miRNA-containing mirtrons
have been predicted by bioinformatic analysis of deep
sequencing data [14]. Nevertheless, their dependence on
splicing was experimentally validated only for two human
miRNAs located in conventional mirtrons, hsa-miR-877-
5p and hsa-miR-1226-3p [16, 17]. Moreover, there is no
convincing evidence for the participation of splicing ma-
chinery in biogenesis of miRNAs processed from 5′-tailed
mirtrons, the most abundant subtype accounting for 86 %
of all predicted mirtrons [14]. Likewise, for 3′-tailed mir-
tronic miRNAs, the splicing dependency was determined
only in Drosophila [28]. Therefore, direct experimental
evidence is necessary to confirm assignment of miRNAs
to the mirtron pathway. In the present study, we experi-
mentally proved that hsa-miR-1227-3p, hsa-miR-1229-3p,
and hsa-miR-1236-3p derived from conventional mirtrons
are processed by the splicing machinery. Meanwhile,
splicing was not strictly required for the maturation of
hsa-miR-1238-3p, previously annotated as mirtron-
encoded miRNA [12, 15]. Indeed, Wen et al. recently re-
classified the hsa-mir-1238 mirtron in miRBase based on
more stringent bioinformatic criteria applied for mirtron
evaluation [14]. Despite successful experimental validation
of mirtronic miRNAs derived from conventional mirtrons,
analysis of the annotated 5′-tailed mirtrons containing
hsa-miR-3064-5p and hsa-miR-6515-5p or 3′-tailed mir-
trons with hsa-miR-3940-5p and hsa-miR-6850-5p re-
vealed no splicing requirement for the biogenesis of the
intron-derived miRNAs. Thus, it is still an open question
whether 5′- or 3′-tailed mirtrons actually exist in mam-
mals. Overall, five out of nine tested human mirtrons gen-
erate miRNA irrespective of splicing. Similarly, several
groups reported that only two of three [29] and two of
four [16] predicted mirtronic miRNA candidates mature
via a mirtron biogenesis pathway. These observations
highlight the relevance of experimental validation of pre-
dicted mirtrons.
Mirtron-encoded miRNAs were predominantly found
to occur in young, recently emerged genes [30]. Despite
their relatively short evolution, the newly evolved miRNAs
are incorporated into beneficial regulatory networks [31].


























































Fig. 4 Different splicing factors can be involved in the biogenesis of specific mirtronic miRNAs. a The amount of SRSF1 and SRSF2 proteins markedly
increased in transfected HCT116 cell line. Western-blot analysis was carried out on nuclear extracts of cells transfected with empty vector
pcDNA3 (-) or plasmid containing recombinant SRSF1 gene (pSRSF1) or SRSF2 gene (pSRSF2). Beta-actin was used as an internal loading
control. b Splicing factor-dependent alterations of endogenous mirtronic miRNA expression levels were determined using RT-qPCR. The
mean values were calculated for three (SRSF1) and five (SRSF2) biological replicates. *Statistically significant results, p < 0.05
Table 4 Change of mirtronic miRNA expression levels in response to the overexpression of splicing factors
Overexpressed splicing factor Change of mirtronic miRNA expression levels, folds (p value)
miR-1226 miR-1227 miR-1229
SRSF1 (3.2 ± 0.6-fold) 1.5 ± 0.6 (p = 0.23) −1.1 ± 0.4 (p = 0.47) 1.7 ± 0.4a (p = 0.05)
SRSF2 (1.6 ± 0.5-fold) 1.5 ± 0.8 (p = 0.15) 1.9 ± 0.7a (p = 0.008) 1.4 ± 0.3a (p = 0.008)
A significance level of 0.05 was applied as a cutoff value
aStatistically significant results
Butkytė et al. Clinical Epigenetics  (2016) 8:33 Page 7 of 11
important functional roles in post-mitotic neurons in the
mammalian brain [32]; however, very little is known about
their expression in cancerous cells. In this study, cell line-
specific profiles of miRNAs processed from conventional
mirtrons, hsa-miR-1226-3p, hsa-miR-1227-3p, hsa-miR-
1229-3p, and hsa-miR-1236-3p, in seven various pancre-
atic, kidney, colorectal, and stomach cancer cell lines were
identified (Table 2). The miRNA variability in cancer cell
lines was determined by changes in abundance of two
mirtronic miRNAs, hsa-miR-1229-3p and hsa-miR-1236-
3p, while the expression levels of hsa-miR-1226-3p and
hsa-miR-1227-3p declined in all tested cancer cell lines
compared to those in HEK 293A. Remarkably, hsa-mir-
1229-3p is upregulated in cell lines derived from meta-
static sites and downregulated in primary tumor lines.
However, further studies are required to assess whether
miR-1229-3p is associated with the metastatic potential of
human tumors.
To further increase the predictive value for clinical
applications, we extended studies of these mirtronic
miRNAs to a number of primary pancreatic, colorectal,
stomach cancerous and healthy tissues (Fig. 3). We pre-
sume that analysis of non-paired cohorts of tumoral and
non-tumoral samples allows a better estimation of miRNA
expression changes, since healthy tissues are certainly not
affected by cancerogenesis. Three mirtron-derived miR-
NAs showed organ-specific profiles in cancerous tissues
of the digestive system. T3 stage pancreatic tumors exhib-
ited a decline of the hsa-miR-1227-3p and hsa-miR-1236-
3p expression. The levels of hsa-miR-1226-3p decreased
in the T3 stage colorectal but conversely increased in the
stomach cancer tissues. Remarkably, hsa-mir-1229-3p,
which was upregulated in the metastatic site-derived cell
lines, exhibited no expression change in the primary tu-
mors. Previous studies demonstrated that cellular levels of
hsa-miR-1226-3p and hsa-miR-1236-3p inversely correlate
with cancerogenesis in breast and hepatoma cancer cells,
respectively [20, 33]. Taken together, these results suggest
that dysregulation of conventional mirtronic miRNAs
could lead to the initiation and progression of specific hu-
man cancers. Moreover, the development of new medical
applications can be based on artificial mirtron-mediated
gene silencing platforms. As promising and affordable
tools, they surpass conventional RNA interference (RNAi)
approaches and allow to consolidate the high therapeutic
potential of RNAi and protein-coding genes in specific cell
types [34–36]. For example, hsa-miR-1226-3p processed
from an artificial conventional mirtron effectively silences
aberrant myotonic dystrophy protein kinase [35], mmu-
miR-1224 leucine-rich repeat serine/threonine-protein
kinase 2, and α-synuclein Parkinson disease-associated
genes [36], while an artificial 3′-tailed mirtron knocks
down the expression of the vascular endothelial growth
factor A [34].
It is known from previous studies that canonical
miRNA biogenesis and splicing mechanisms are directly
coupled [37]. The binding of splicing regulatory proteins
SRSF1 and hnRNPA1 to the stem loop of pri-miR-7 and
pri-miR-18a, respectively, appears to affect Drosha pro-
cessing of primary miRNA transcripts [26, 33]. Similarly,
KHSPR promotes the maturation of a subset of miRNA
precursors, such as pre-let-7a, pre-mir-1, and pre-mir-15
[38]. Consequently, SFs regulate both splicing and ca-
nonical miRNA processing, but little is known about
their function in the biogenesis of miRNAs hosted on
mirtrons. It has been only observed in patients with
myelodysplastic syndrome that SF3B1 and SRFS2 muta-
tions are associated with a downregulated expression of
miRNAs derived from the putative 5′-tailed mirtrons
hsa-miR-3605-5p and hsa-miR-4728-5p, respectively [5].
Our results revealed that increased nuclear levels of
SRSF1 in tested HCT116 cells significantly enhanced the
hsa-miR-1229-3p expression, while upregulated SRSF2
increased the abundance of the mirtronic miRNAs hsa-
miR-1227-3p and hsa-miR-1229-3p. To our knowledge,
these data, for the first time, demonstrate that an indi-
vidual SF can directly act as a positive regulator for par-
ticular species of mirtronic miRNAs.
To gain insight into the regulation of mirtronic
miRNA by components of splicing machinery, we corre-
lated the mirtronic miRNA levels with the expression
profiles of five SFs in different human digestive and ex-
cretory system cell lines or pancreatic, colorectal, and
stomach tissues. It should be noted that RNA (this
paper) and proteins [39] were purified simultaneously
from the same tissue or cell line samples. The experi-
ments revealed a reduced expression of SRSF1 and
SRSF2 in pancreatic, kidney, colorectal, and stomach
cancer cell lines as well as in cancer tissues — SRSF2
was downregulated in stomach tumors, while SRSF1 was
reduced in all types of tested tumors [39]. Accordingly,
tumor-promoting roles of SRSF1 and SRSF2 have been
reported in various cancer types [40, 41]. Still, reduced
expression of SRSF1 and SRSF2 proteins in the cancer
cells [39] weakly correlated with signature of mirtronic
miRNA expression (Tables 2 and 3). For example, no ob-
vious differences in abundance of hsa-miR-1229-3p were
seen among samples collected from the pancreas, colon,
or stomach, notwithstanding a ~14-fold under-
expression of SRSF1 and a sevenfold of SRSF2 in the
colorectal and stomach cancerous tissues. At a first
glance, these results seem to contradict the finding that
these SFs positively modulate the levels of mirtronic
miRNAs under overexpression conditions in the model
cell line HCT116 (Fig. 4). However, first, a dual role for
SRSF1 as a splicing activator and repressor was pro-
posed [42]. Second, the expression of other factors
involved in the regulation of splicing, U2AF35, U2AF65,
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and KHSRP, also significantly varied among cell lines
and tumors [39]. In addition, the spliceosome mutations
may affect the expression of miRNA genes [5]. Thus,
biogenesis of mirtronic miRNAs could be regulated by
different SFs or by a network of antagonistic and collab-
orative interactions of spliceosome components. In gen-
eral, our data imply that a combination of multiple SFs
may differently affect the biogenesis of mirtron-derived
miRNAs, making it extremely difficult to predict par-
ticular effects of individual spliceosome components on
the mirtron processing.
Conclusions
In this study, we experimentally validated three novel
splicing-dependent miRNAs processed from mirtrons,
hsa-miR-1227-3p, hsa-miR-1229-3p, and hsa-miR-1236-
3p. The expression analysis, for the first time, identified
specific profiles of mirtronic miRNAs in cancerous cells
and tumors suggesting their potential for exploiting as
diagnostic tools. Finally, we demonstrated that the
SRSF1 and SRSF2 SFs contribute to the biogenesis of
mirtronic hsa-miR-1227-3p and hsa-miR-1229-3p.
Methods
Human cell cultures
HEK 293A (embryonic kidney), PANC-1 (pancreas/duct,
epithelioid carcinoma), SU.86.86 (pancreas, ductal carcin-
oma; derived from a metastatic site: liver), T3M4 (pancreas,
ductal carcinoma; metastasis), CaKi-1 (kidney, clear cell
carcinoma, derived from a metastatic site: skin), 786-O
(kidney, renal cell adenocarcinoma), HCT116 (colon, colo-
rectal carcinoma), and KATOIII (stomach, gastric carcin-
oma; derived from a metastatic site: pleural effusion and
supraclavicular and axillary lymph nodes and Douglas cul-
de-sac) cells were cultured in the RPMI 1640 medium
supplemented with 10 % fetal bovine serum and penicillin
(100 U/ml) and streptomycin (100 μg/ml).
Tumors and healthy tissues
Collection of surgically removed tumor and healthy tis-
sue samples was described previously [39]. In total 29
healthy (8 pancreatic, 6 colorectal, 15 stomach) ant 37
tumor (12 pancreatic, 12 colorectal, 13 stomach) tissues
were used for the experiments. The experiments were
undertaken with the understanding and written consent
of each subject, and the study conforms to The Code of
Ethics of the World Medical Association (Declaration of
Helsinki).
Construction of plasmids
Minigene constructs of 1226/DHX30 (from exon 19 to
exon 21; mirtronic intron 20), 1227/PLEKHJ1 (exons 5 to
7; mirtronic intron 5), 1229/MGAT4B (exons 11 to 13;
mirtronic intron 12), 1236/NELFE (exons 3 to 4; mirtronic
intron 3), 1238/ATG4D (exons 7 to 9; mirtronic intron 8),
3064/DDX5 (exons 10 to 12, mirtronic intron 11), 3940/
KHSRP (exons 13 to 15, mirtronic intron 14), 6515/CARL
(exons 5 to 7, mirtronic intron 5), and 6850/RPL8 (exons
2 to 4, mirtronic intron 2) were amplified from human
Jurkat cell genomic DNA (ThermoFisher Scientific) using
Phusion High-Fidelity DNA Polymerase (ThermoFisher
Scientific) according to the manufacturer’s instructions.
PCR products were digested with BamHI and HindIII re-
striction endonucleases, except 3940/KHSRP, 6515/CARL
(digested with HindIII and EcoRI), and 6850/RLP8 (EcoRI
and NotI), and inserted into pcDNA3 plasmid. PCR intro-
duced 5′- and 3′-splice site mutations by using Phusion
High-Fidelity DNA Polymerase with primers containing
splicing site mutations (Additional file 2: Table S2). Amp-
lification products were circularized using T4 DNA ligase
(all enzymes were obtained from ThermoFisher Scientific).
All final plasmid constructs were confirmed by Sanger
sequencing.
The expression plasmids pSRSF1 and pSRSF2 were
constructed by insertion of SRSF1 isoform 1 and SRSF2-
coding DNA sequence into the pcDNA3 vector, respect-
ively. Total RNA, extracted from HCT116 cells, was
converted to complementary DNA (cDNA) using Rever-
tAid RT kit (ThermoFisher Scientific). The CDS of genes
were PCR-amplified using primers containing HindIII and
BamHI sites (Additional file 2: Table S1), digested with
appropriate restriction enzymes and the resulting frag-
ments ligated into pcDNA3. Clones were confirmed by
DNA sequence analysis.
Transfection
HTC116 cells were cultured in RPMI 1640 media. Transi-
ent transfections were performed using Lipofectamine
LTX transfection reagent (Invitrogen) according to the
manufacturer’s instructions. For overexpression assay,
HTC116 cells were seeded in 60-mm plates and allowed to
grow for 24 h prior to transfection with pcDNA3-SRSF1,
pcDNA3-SRSF2, pcDNA3-DHX30, pcDNA3-PLEKHJ1,
pcDNA3-MGAT4B, pcDNA3-NELFE, pcDNA3-ATG4D,
pcDNA3-DDX5, pcDNA3-KHSRP, pcDNA3-CARL, or
pcDNA3-RPL8 constructs. A pcDNA3 vector was trans-
fected to be used as a RT-qPCR reference. RNAs and
proteins were isolated after 48 h. The experiments were in-
dependently repeated three times.
RNA isolation
RNA from cell lines was isolated using an RNAzol® RT
reagent according to the manufacturer’s instructions
(Molecular Research Center). Native proteins for SF
studies by Jakubauskienė et al. [39] and total RNA used
for the miRNA analysis (present paper) from tumors
and healthy tissues were purified from the same sample
using mirVana™ PARIS™ kit (ThermoFisher Scientific)
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according to the manufacturer’s instructions. Fraction of
short RNAs (<200 nt) was used for miRNA RT and qPCR
experiments. The integrity of long RNAs (>200 nt) was
assessed using an Agilent 2100 Bioanalyzer or agarose
(1 %) gel electrophoresis. To avoid DNA contamination
before RT reaction, the RNA samples were treated with
DNase I (ThermoFisher Scientific) according to the manu-
facturer’s instructions.
Real-time RT-PCR of miRNAs
Each 20 μl of the RT reaction in the RT buffer contained
200 units of RevertAid Reverse Transcriptase (Thermo-
Fisher Scientific), 1 mM dNTP (ThermoFisher Scientific),
1 μM RT primer mixture (Metabion), 16 units of RNase
inhibitor RiboLock (ThermoFisher Scientific), and 200 ng
of RNA. The mixture was incubated for 20 min at 25 °C
and for 60 min at 37 °C and then heat-inactivated for
10 min at 70 °C. Real-time PCR was performed with SYBR
Green PCR Master Mix (ThermoFisher Scientific) (35 cy-
cles): initial denaturation for 10 min at 95 °C, followed by
three cycles of amplification 15 s at 95 °C, 1 min at 55 °C,
and 30 s at 60 °C, then 32 cycles 10 s at 95 °C and 30 s at
60 °C. Relative quantification of changes in the miRNA
expression levels was performed using the comparative Ct
(threshold cycle) method with normalization to the ex-
pression of endogenous control RNU48. Specific miRNA
and RNU48 primers are provided in Additional file 2:
Table S3. The RT primer mixture was composed of two
primers: specific miRNA and RNU48. Quantitative PCR
analysis was carried out on Rotor-Gene 6000 (Corbett Life
Science) equipment. Part of RT-PCR products were
inserted into pUC19 plasmid, and constructs were con-
firmed by sequence analysis.
Detection of spliced and unspliced forms of mRNA
Spliced and unspliced DHX30, PLEKHJ1, MGAT4B,
NELFE, ATG4D, DDX5, KHSRP, CARL, and RPL8 mRNA
isoforms were detected by RT-PCR. cDNA synthesis was
carried out using RevertAid Reverse Transcriptase and
random hexamer primers according to the manufacturer’s
(ThermoFisher Scientific) instructions. PCR was carried
out using TrueStart Hot Start Taq DNA Polymerase
(ThermoFisher Scientific) according to the manufacturer’s
instructions. Amplification products were separated on
1 % agarose gel. TBP was used as loading control. Se-
quences of primers specific for the outer exons of mirtro-
nic introns are provided in Additional file 2: Table S4.
Protein preparation from cell cultures and western
blotting
The nuclear fractions of proteins for western blotting were
prepared from cell cultures using the NE-PER Nuclear
and Cytoplasmic Extraction Reagents kit (ThermoFisher
Scientific) according to the manufacturer’s instructions.
Proteins were separated on a 10 % SDS–polyacrylamide
gel and transferred onto the membrane. The membrane
was incubated with appropriate primary antibody: anti-
SRSF1 (Santa Cruz), anti-SRSF2 (Abcam), or anti-β-actin
(Abcam), and washed and incubated with secondary anti-
body (Dako). The membrane was developed using TMB
reagent (Sigma-Aldrich). All data were quantitated using
MultiGauge software (Fujifilm). β-Actin expression was
used for data normalization.
Statistical analysis
Statistical analysis was performed using Sigma Plot soft-
ware v. 11. Two-tailed unpaired Student’s t test and
Mann-Whitney rank sum test were used to compare the
differences in distribution between experimental results. A
value of p < 0.05 was considered statistically significant.
Additional files
Additional file 1: Figure S1. Splicing-dependent and Drosha-
independent biogenesis of mirtronic miRNAs. The spliceosome, a multi-
component ribonucleoprotein complex, cuts out the introns from
pre-mRNA transcripts and splices together the exons resulting in the
maturation of messenger RNA. Lariats of the introns are debranched
by lariat debranching enzyme. The produced structures fold into pre-
miRNA hairpins that are exported to the cytoplasm. After the cleavage by
Dicer, the guide miRNA strand of mature miRNA/miRNA* duplex is loaded
into functional Ago complex. Figure S2. Schematic representation
of human genes containing mirtronic miRNAs. Schemes represent
protein-coding genes, harboring reside-verified mirtronic miRNA hsa-miR-
1226-3p, putative conventional mirtronic miRNAs hsa-miR-1227-3p, hsa-miR-
1229-3p, and hsa-miR-1238-3p, mirtronic miRNAs, located in 5′-tailed
mirtrons hsa-miR-3064-5p and hsa-miR-6515-5p and mirtronic miRNAs,
located in 3′-tailed mirtrons hsa-miR-3940-5p and hsa-miR-6850-5p.
Green boxes and lines indicate exons and introns of protein-coding
genes, respectively. Purple boxes indicate 5′ and 3′ untranslated regions.
Mirtrons containing previously mentioned mirtronic miRNAs are depicted
as red lines. Full sequence of mirtrons (except of hsa-miR-3064) is written
above each scheme, where sequence of more abundant miRNA of the
hairpin is marked in red, less abundant in blue, and tail is marked in
green. Dashes beneath the schemes show minigenes positions in the
genes. Figure S3. Expression of mirtronic miRNAs in cancer cell lines.
miRNA expression normalized to RNU48 and compared to HEK 293A.
The experiments were performed in at least three biological replicates.
The error bars represent calculated values for standard deviation. Fold
changes higher than 1.5 were statistically significant (p < 0.05). Figure S4.
The position of splicing signals predicted by online bioinformatics tool
Human Splicing Finder. SRSF1-specific targets are highlighted in yellow,
SRSF2-specific in green. Sequence of mirtrons is written as italicized red
text, exon sequence normal black text. (PDF 750 kb)
Additional file 2: Table S1. Primers for DHX30, PLEKHJ1, MGAT4B, NELFE,
ATG4D, DDX5, KHSRP, CARL, and RPL8 gene amplification. Table S2. Primers
used for 5′ and 3′ splicing site mutagenesis. Table S3. Specific miRNA and
RNU48 primers for RT-qPCR. Table S4. Primers for spliced and unspliced gene
form detection. (PDF 393 kb)
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